CRISPR Therapeutics AG

BOVESPA:C2RS34 Stock Report

Market Cap: R$21.1b

CRISPR Therapeutics Management

Management criteria checks 3/4

CRISPR Therapeutics' CEO is Sam Kulkarni, appointed in Dec 2017, has a tenure of 6.5 years. total yearly compensation is $12.32M, comprised of 5.9% salary and 94.1% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth R$66.20M. The average tenure of the management team and the board of directors is 5.2 years and 5.5 years respectively.

Key information

Sam Kulkarni

Chief executive officer

US$12.3m

Total compensation

CEO salary percentage5.9%
CEO tenure7yrs
CEO ownership0.3%
Management average tenure5.2yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sam Kulkarni's remuneration changed compared to CRISPR Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$240m

Jun 30 2024n/an/a

-US$266m

Mar 31 2024n/an/a

-US$217m

Dec 31 2023US$12mUS$725k

-US$154m

Sep 30 2023n/an/a

-US$354m

Jun 30 2023n/an/a

-US$416m

Mar 31 2023n/an/a

-US$524m

Dec 31 2022US$21mUS$700k

-US$650m

Sep 30 2022n/an/a

-US$681m

Jun 30 2022n/an/a

-US$633m

Mar 31 2022n/an/a

US$312m

Dec 31 2021US$17mUS$670k

US$378m

Sep 30 2021n/an/a

US$412m

Jun 30 2021n/an/a

US$447m

Mar 31 2021n/an/a

-US$392m

Dec 31 2020US$9mUS$625k

-US$349m

Sep 30 2020n/an/a

-US$211m

Jun 30 2020n/an/a

US$20m

Mar 31 2020n/an/a

US$46m

Dec 31 2019US$16mUS$550k

US$67m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$200m

Mar 31 2019n/an/a

-US$185m

Dec 31 2018US$10mUS$518k

-US$165m

Sep 30 2018n/an/a

-US$117m

Jun 30 2018n/an/a

-US$91m

Mar 31 2018n/an/a

-US$75m

Dec 31 2017US$7mUS$405k

-US$68m

Compensation vs Market: Sam's total compensation ($USD12.32M) is above average for companies of similar size in the BR market ($USD1.19M).

Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.

CEO

Sam Kulkarni (46 yo)

7yrs

Tenure

US$12,322,196

Compensation

Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...

Leadership Team

NamePositionTenureCompensationOwnership
Samarth Kulkarni
CEO & Chairman7yrsUS$12.32m0.31%
R$ 66.2m
Raju Prasad
Chief Financial Officer1.8yrsUS$5.91m0.012%
R$ 2.5m
James Kasinger
General Counsel & Secretary7.6yrsUS$3.51m0.073%
R$ 15.5m
Shaun Foy
Founderno datano datano data
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datano datano data
Craig Mello
Scientific Founder & Advisory Board Memberno datano datano data
Chad Cowan
Scientific Founderno datano datano data
Matthew Porteus
Scientific Founder & Advisory Board Memberno datano datano data
Daniel Anderson
Scientific Founder & Advisory Board Memberno datano datano data
Julianne Bruno
Chief Operating Officerless than a yearno data0.016%
R$ 3.4m
Stephen Kennedy
Head of Technical Operations5.2yrsno datano data
Susan Kim
Vice President of Corporate Communications & Investor Relationsno datano datano data

5.2yrs

Average Tenure

49yo

Average Age

Experienced Management: C2RS34's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Samarth Kulkarni
CEO & Chairman6.5yrsUS$12.32m0.31%
R$ 66.2m
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datano datano data
Craig Mello
Scientific Founder & Advisory Board Memberno datano datano data
Matthew Porteus
Scientific Founder & Advisory Board Memberno datano datano data
Daniel Anderson
Scientific Founder & Advisory Board Memberno datano datano data
Douglas Treco
Lead Independent Director4.5yrsUS$552.56k0.0023%
R$ 494.9k
Ali Behbahani
Independent Director9.7yrsUS$545.06k0.00032%
R$ 67.7k
Katherine High
Independent Director5.5yrsUS$532.56k0%
R$ 0
Simeon George
Independent Director9.7yrsUS$542.56k0%
R$ 0
Stephen Elledge
Member of Scientific Advisory Boardno datano datano data
John Greene
Independent Director5.5yrsUS$555.06k0%
R$ 0
H. Fleming
Independent Director3.5yrsUS$536.24k0%
R$ 0

5.5yrs

Average Tenure

58yo

Average Age

Experienced Board: C2RS34's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CRISPR Therapeutics AG is covered by 46 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Evan SeigermanBMO Capital Markets Equity Research